MiR-195 and Its Target SEMA6D Regulate Chemoresponse in Breast Cancer.

Area of Science:

• Oncology
• Molecular Biology
• Genomics

Background:

• Poor prognosis primary breast cancers often recur despite cytotoxic chemotherapy.
• Identifying molecular drivers of chemoresistance is crucial for improving treatment outcomes.
• Comparing pre- and post-chemotherapy tumors can reveal mechanisms of therapy resistance.

Purpose of the Study:

• To identify microRNAs associated with chemotherapy resistance in breast cancer.
• To define microRNA target genes involved in chemoresistance.
• To evaluate microRNA targets as predictors of chemotherapy response.

Main Methods:

• Laser microdissection of matched breast cancer tissues (n=5) pre- and post-chemotherapy.
• MicroRNA expression profiling using qPCR arrays.
• In vitro manipulation of microRNA/mRNA expression in breast cancer cell lines (MCF7, MDA-MB-175) and assessment of chemoresponse.
• Identification of microRNA targets via RNA-sequencing and bioinformatic analysis.
• Survival correlation analysis using the METABRIC dataset (n=1979).

Main Results:

• miR-195 and miR-26b were upregulated post-chemotherapy, correlating with increased chemoresistance.
• SEMA6D was identified as a direct target of these microRNAs.
• Reduced SEMA6D expression was significantly associated with chemoresistance.
• Low SEMA6D expression predicted poor survival after chemotherapy in patients.

Conclusions:

• MicroRNAs and their targets play a significant role in chemotherapy response.
• SEMA6D is a potential predictive marker for chemotherapy response in breast cancer.
• Targeting SEMA6D or related microRNAs could offer novel chemosensitization strategies.